NURS 615 UPDATED SCRIPT 2026
PRACTICE SOLUTIONS GRADED A+
● What is a Black Box Warning: Answer: is considered a
contraindication to administer that drug.
● What is the drugs half-life? Answer: Half-life specifically means the
amount of time it takes for an administered drug to be halfway cleared
from the system.
● Peak of action: Answer: the time between drug administration and
maximum concentration of drug in the blood stream. Best therapeutic
effect.
● Duration of action: Answer: the time between onset of action and
metabolism of drug below the minimum needed for an effect. The length
of time you have the drug in your system.
● According to the WHO what is the first step in the prescribing
process? Answer: The first step is to define the patient's problem
● The second step is to Answer: specify the therapeutic objective
● The third step is to Answer: choose which drug or treatment is needed.
,● Step 4 of the WHO approach: Answer: Start the treatment
● Step 5 of the WHO approach: Answer: Educate the patient
● Step 6 of the WHO approach: Answer: Monitor the treatment
● Phase 1 of drug development: Answer: The drug is tested on healthy
volunteers
● Phase 2 of drug development: Answer: trials with people who have the
disease for which the drug is thought to be effective
● Phase 3 of drug development: Answer: Large numbers of patients in
medical research centers receive the drug in phase 3. This larger
sampling provides information about infrequent or rare adverse effects.
The FFA will approve a new drug application if phase 3 studies are
satisfactory.
● Phase 4 of drug development: Answer: This phase is voluntary and
involves postmarket surveillance of the drug's therapeutic effects at the
completion of phase 3. The pharmaceutical company receives reports
from doctors and other health care professionals about the therapeutic
results and adverse effects of the drug. Some medications, for example,
, have been found to be toxic and have been removed from the market
after their initial release.
● Explain first pass metabolism Answer: much of the drug is lost in the
absorption process. The liver metabolizes many drugs, thus reduces the
bioavailabilty of the drug.
● What is the fasted route of absorption: Answer: The fastest route of
absorption is inhalation, and not as mistakenly considered the IV
administration.
● Why does the GI tract take longer to absorb? Answer: The GI tract is
lined with epithelial cells; drugs must permeate through these cells in
order to be absorbed into the circulatory system.
● What is One particular cellular barrier that may prevent absorption of
a given drug? Answer: the cell membrane. Cell membranes are
essentially lipid bilayers which form a semipermeable membrane. Pure
lipid bilayers are generally permeable only to small and uncharged
solutes, hence whether or not a molecule is ionized will affect its
absorption, since ionic molecules are charged.
● What is solubility? Answer: Solubility favors charged species,
permeability favors neutral species. Some molecules have special
exchange proteins and channels to facilitate movement from the lumen
into the circulation.
PRACTICE SOLUTIONS GRADED A+
● What is a Black Box Warning: Answer: is considered a
contraindication to administer that drug.
● What is the drugs half-life? Answer: Half-life specifically means the
amount of time it takes for an administered drug to be halfway cleared
from the system.
● Peak of action: Answer: the time between drug administration and
maximum concentration of drug in the blood stream. Best therapeutic
effect.
● Duration of action: Answer: the time between onset of action and
metabolism of drug below the minimum needed for an effect. The length
of time you have the drug in your system.
● According to the WHO what is the first step in the prescribing
process? Answer: The first step is to define the patient's problem
● The second step is to Answer: specify the therapeutic objective
● The third step is to Answer: choose which drug or treatment is needed.
,● Step 4 of the WHO approach: Answer: Start the treatment
● Step 5 of the WHO approach: Answer: Educate the patient
● Step 6 of the WHO approach: Answer: Monitor the treatment
● Phase 1 of drug development: Answer: The drug is tested on healthy
volunteers
● Phase 2 of drug development: Answer: trials with people who have the
disease for which the drug is thought to be effective
● Phase 3 of drug development: Answer: Large numbers of patients in
medical research centers receive the drug in phase 3. This larger
sampling provides information about infrequent or rare adverse effects.
The FFA will approve a new drug application if phase 3 studies are
satisfactory.
● Phase 4 of drug development: Answer: This phase is voluntary and
involves postmarket surveillance of the drug's therapeutic effects at the
completion of phase 3. The pharmaceutical company receives reports
from doctors and other health care professionals about the therapeutic
results and adverse effects of the drug. Some medications, for example,
, have been found to be toxic and have been removed from the market
after their initial release.
● Explain first pass metabolism Answer: much of the drug is lost in the
absorption process. The liver metabolizes many drugs, thus reduces the
bioavailabilty of the drug.
● What is the fasted route of absorption: Answer: The fastest route of
absorption is inhalation, and not as mistakenly considered the IV
administration.
● Why does the GI tract take longer to absorb? Answer: The GI tract is
lined with epithelial cells; drugs must permeate through these cells in
order to be absorbed into the circulatory system.
● What is One particular cellular barrier that may prevent absorption of
a given drug? Answer: the cell membrane. Cell membranes are
essentially lipid bilayers which form a semipermeable membrane. Pure
lipid bilayers are generally permeable only to small and uncharged
solutes, hence whether or not a molecule is ionized will affect its
absorption, since ionic molecules are charged.
● What is solubility? Answer: Solubility favors charged species,
permeability favors neutral species. Some molecules have special
exchange proteins and channels to facilitate movement from the lumen
into the circulation.
